Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted siRNAs for treating bladder cancer.

Achieving an effective biocompatible system for siRNAs delivery to the tumor site remains a significant challenge. Selenium nanoparticles (SeNPs) modified by chitosan (CS) and hyaluronic acid (HA) were fabricated for siRNAs () delivery to the bladder cancer cells. The HA-CS-SeNP@siPLK1 efficacy was evaluated using and models. HA-CS-SeNP@siPLK1 was selectively internalized into T24 cells through clathrin-mediated endocytosis. Treatment with HA-CS-SeNP@siPLK1 successfully silenced the gene, inhibited cell proliferation and induced cell cycle arrest . HA-CS-SeNP@siPLK1 could also inhibit tumor growth without causing systemic toxicity. Our results suggest that HA-CS-SeNPs may provide a good vehicle for delivering to the bladder tumor site.